| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Brazzell Romulus K | Head of Research and Development and Chief Medical Officer | C/O KALA BIO, INC., 1167 MASSACHUSETTS AVENUE, ARLINGTON | /s/ Mary Reumuth, Attorney-in-Fact | 04 Jun 2025 | 0001298079 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | KALA | Common Stock | Sale | $13,789 | -3,687 | -4% | $3.74 | 87,949 | 03 Jun 2025 | Direct | F1, F2, F3 |
| Id | Content |
|---|---|
| F1 | This sale was made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 9, 2020 to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's restricted stock units ("RSUs") granted on May 31, 2023. |
| F2 | The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.52 to $4.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. |
| F3 | Includes 52,402 unvested RSUs. |
Head of Research and Development and Chief Medical Officer